Navigation Links
Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
Date:7/1/2009

TUSTIN, Calif., July 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has been awarded a European patent for a novel device and methods for linking biological agents to labels for diagnostic and therapeutic applications. The technology, which is known as In-Line labeling, was developed for the production of radiolabeled anti-cancer antibodies, but is applicable to other agents as well. A study published today in the July 2009 issue of The Journal of Nuclear Medicine confirms that In-Line labeling can dramatically reduce the complexity and cost of producing radiolabeled cancer drugs(1). In-Line labeling is already being used for the production of Peregrine's radiolabeled antibody Cotara(R), currently in Phase II trials for the treatment of glioblastoma multiforme, a deadly form of brain cancer.

Radiolabeled drugs are important for the diagnosis and treatment of multiple cancers. However, the labeling process itself has been complex, slow, expensive and challenging to scale-up, which may have contributed to the historic underutilization of these valuable agents. Peregrine's new process replaces the traditional "batch" labeling method with a continuous In-Line flow process, where the individual constituents are kept separate at the beginning and then are allowed to flow together in a reaction tube, where the labeling process occurs. The In-Line process can prepare enormous amounts of radiolabeled product by simply keeping the constituents flowing continuously along the tube.

Missag H. Parseghian, Ph.D., senior director of R&D at Peregrine and senior author of the new publication, commented, "The continuous In-Line process requires no sophisticated instrumentation and can be implemented in almost any radiation facility. Importantly, performance-related characteristics
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Illinois (PRWEB) December 22, 2014 ITRA ... tenants and occupiers of commercial real estate, has further ... new offices in Perth and Brisbane, Western Australia, reports ... of directors. , ITRA Global / ACORPP (Australian ... totally independent consultancy company providing property services to a ...
(Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
(Date:12/19/2014)...  Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... a privately held company based in ... a big data platform for centralized management and ... proprietary on-market Genomic Management Solution, Bina-GMS 1 , ... fast and scalable analyses to maximize the value ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/fhh9rj/technology ) ... Innovations in Smart Fabrics (Technical Insights)" report ... http://photos.prnewswire.com/prnh/20130307/600769 The Research Service titled ... assessment on technological advancements and market for Smart ... 1. The Smart Fabrics market is expected to ...
Breaking Biology Technology:ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Technology Innovations in Smart Fabrics (Technical Insights) 2
... March 11 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a ... has entered into two definitive license agreements with University Health ... Toronto, Ontario , granting Trillium exclusive worldwide rights to ... cell transplantation and cancer. , ...
... LEIDEN, The Netherlands and ... ProFibrix B.V., a leader in the development of innovative,products ... the first Phase II trial testing its unique new ... show compelling safety and efficacy (time to hemostasis),profiles for ...
... Neurocrine Biosciences, will be presenting at the Roth 22nd Annual OC Growth Conference in Laguna Niguel . , ... , , ... ... ...
Cached Biology Technology:Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 2Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 3ProFibrix Reports Phase II Results of Hemostasis Product Fibrocaps(TM) and Appoints New Chief Medical Officer 2ProFibrix Reports Phase II Results of Hemostasis Product Fibrocaps(TM) and Appoints New Chief Medical Officer 3Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference 2
(Date:12/22/2014)...  The 2014 Holiday Season may be the ... Market Intelligence reports that the long anticipated floodgates ... forecasts that intensifying demand for smart phones, tablets, ... drive a global market of 2.5 billion users ... According to Maxine Most ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ... new funding to expand its team and bring LaunchKey ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... University have discovered a phenomenon never seen before in plants ... formed. In research published online in Proceedings ... Aug. 20, the team found that one member of a ... cascade of genes involved in forming wood, which includes a ...
... Efforts to Prevent Microbial Stowaways on Interplanetary Spacecraft , ... and the spacecraft themselves, inadvertently select for the organisms ... journeys in space. This has the risk of thwarting ... well as samples brought back to earth, according to ...
... a gene that enables rice plants to produce around 20% ... limited, plant nutrient. The discovery unlocks the potential to ... value phosphorus-deficient land allowing them to grow more rice to ... called PSTOL1 which stands for Phosphorus Starvation Tolerance ...
Cached Biology News:August 2012 tips from the journals of the American Society for Microbiology 2August 2012 tips from the journals of the American Society for Microbiology 3August 2012 tips from the journals of the American Society for Microbiology 4August 2012 tips from the journals of the American Society for Microbiology 5August 2012 tips from the journals of the American Society for Microbiology 6August 2012 tips from the journals of the American Society for Microbiology 7Underground solution to starving rice plants 2Underground solution to starving rice plants 3
... Cycler is the ideal instrument for budget-conscious labs ... PCR applications. Get Applied Biosystems proven ... Save lab space without sacrificing results. ... PCR Technology You Can Afford The ...
... [6331] to Salmonella typhimurium The genus Salmonella ... genus is composed of Gram-negative bacilli that are ... antigens; the "H" or flagellar antigen (phase 1 ... of the LPS moiety) and the "Vi" or ...
... 36 mg/L sodium pyruvate, 50 mg/L streptomycin ... glucose, calcium chloride, and magnesium chloride. The ... in tissue culture is generally attributed to ... Sydney Ringer developed a solution of inorganic ...
... micro 1 is a dramatic breakthrough in accurate, ... with 10nL resolution, the micro 1 has unique ... And, the micro 1 never needs re-calibration as ... Screen programming on an LCD Display , Graphical ...
Biology Products: